The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 01, 2011
Filed:
May. 22, 2006
Carlos Matute Almau, Leioa-Vizcaya, ES;
María Domercq García, Leioa-Vizcaya, ES;
Alberto Pérez Samartín, Leioa-Vizcaya, ES;
Fernando Pérez Cerdá, Leioa-Vizcaya, ES;
Ainara Vallejo Illarramendi, Leioa-Vizcaya, ES;
Estibaliz Etxebarria Galnares, Leioa-Vizcaya, ES;
Ormaetxea Olatz Pampliega, Leioa-Vizcaya, ES;
Pablo Villoslada Díaz, Leioa-Vizcaya, ES;
Alfredo Rodríguez-antigüedad Zarranz, Leioa-Vizcaya, ES;
Carlos Matute Almau, Leioa-Vizcaya, ES;
María Domercq García, Leioa-Vizcaya, ES;
Alberto Pérez Samartín, Leioa-Vizcaya, ES;
Fernando Pérez Cerdá, Leioa-Vizcaya, ES;
Ainara Vallejo Illarramendi, Leioa-Vizcaya, ES;
Estibaliz Etxebarria Galnares, Leioa-Vizcaya, ES;
Ormaetxea Olatz Pampliega, Leioa-Vizcaya, ES;
Pablo Villoslada Díaz, Leioa-Vizcaya, ES;
Alfredo Rodríguez-Antigüedad Zarranz, Leioa-Vizcaya, ES;
Universidad Del Pais Vasco, , ES;
Abstract
The present invention refers to the use of glutamate transporters, glutamate and EGF to detect the presence of demyelinating diseases in a subject, to determine the status or severity of the same or to monitor the effects of a therapy administered to a subject who suffers from such diseases; to the use of the said markers for the searching, identification, development and evaluation of the efficacy of compounds for the treatment of such diseases, with a view to developing new drugs; to the use of compounds which promote the expression of the EAAT1 and EAAT2 transporters, as well as EGF for the treatment of demyelinating diseases. In a preferred embodiment, the methods and compounds of the invention are applicable to MS.